Proto oncogene protein c-myc inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 3-4 Business Days
DelveInsight’s, “Proto oncogene protein c-myc inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Proto oncogene protein c-myc inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Proto oncogene protein c-myc inhibitors: Overview
cMyc is a 62 kDa protein (439 amino acids) and belongs to the basic helix-loop-helix zipper (bHLHZip) class of transcription factors. cMyc has been implicated in multiple cellular processes, including proliferation, differentiation, apoptosis and metabolism. The four-helix structure of cMyc and MAX binds to DNA sequences, such as E-box motifs (5’-CACGTG -3’), to control transcription of specific genes. These genes have been reported to be involved in chromatin modification, DNA replication, and ribosome and mitochondrial biogenesis. A large number of proofs of principle experiments suggest that targeting cMyc may have considerable therapeutic benefit in human tumors. cMyc binds to the MAX protein and forms dimers, which are necessary for the biological activation of cMyc. Strategies have emerged to inhibit cMyc expression, to interrupt cMyc-Max dimerization, to inhibit cMyc-Max DNA binding, to interfere with key cMyc target genes, and to inhibit cMyc in cancer stem cells (CSCs).
Report Highlights
This segment of the Proto oncogene protein c-myc inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Proto oncogene protein c-myc inhibitors Emerging Drugs
Further product details are provided in the report……..
Proto oncogene protein c-myc inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Proto oncogene protein c-myc inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
Proto oncogene protein c-myc inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Proto oncogene protein c-myc inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Proto oncogene protein c-myc inhibitors drugs.
Proto oncogene protein c-myc inhibitors Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Proto oncogene protein c-myc inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Proto oncogene protein c-myc inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Proto oncogene protein c-myc inhibitors: Overview
cMyc is a 62 kDa protein (439 amino acids) and belongs to the basic helix-loop-helix zipper (bHLHZip) class of transcription factors. cMyc has been implicated in multiple cellular processes, including proliferation, differentiation, apoptosis and metabolism. The four-helix structure of cMyc and MAX binds to DNA sequences, such as E-box motifs (5’-CACGTG -3’), to control transcription of specific genes. These genes have been reported to be involved in chromatin modification, DNA replication, and ribosome and mitochondrial biogenesis. A large number of proofs of principle experiments suggest that targeting cMyc may have considerable therapeutic benefit in human tumors. cMyc binds to the MAX protein and forms dimers, which are necessary for the biological activation of cMyc. Strategies have emerged to inhibit cMyc expression, to interrupt cMyc-Max dimerization, to inhibit cMyc-Max DNA binding, to interfere with key cMyc target genes, and to inhibit cMyc in cancer stem cells (CSCs).
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Proto oncogene protein c-myc inhibitors R&D. The therapies under development are focused on novel approaches for Proto oncogene protein c-myc inhibitors.
This segment of the Proto oncogene protein c-myc inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Proto oncogene protein c-myc inhibitors Emerging Drugs
- RRx-001: EpicentRx Inc.
- WP1066: Moleculin Biotech
Further product details are provided in the report……..
Proto oncogene protein c-myc inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different Proto oncogene protein c-myc inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Proto oncogene protein c-myc inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intravenous
- Oral
- Subcutaneous
- Molecule Type
- Peptides
- Small molecule
- Product Type
Proto oncogene protein c-myc inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Proto oncogene protein c-myc inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Proto oncogene protein c-myc inhibitors drugs.
Proto oncogene protein c-myc inhibitors Report Insights
- Proto oncogene protein c-myc inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Proto oncogene protein c-myc inhibitors drugs?
- How many Proto oncogene protein c-myc inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Proto oncogene protein c-myc inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Proto oncogene protein c-myc inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Proto oncogene protein c-myc inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- EpicentRx Inc.
- Moleculin Biotech
- Peptomyc
- Teva Pharmaceutical Industries
- Plexxikon
- CURACLE
- Aptose Biosciences
- Kintor Pharmaceutical
- Escend Pharmaceuticals
- Hillstream BioPharma
- RRx-001
- WP1066
- OMO 103
- C41443
- PLX 51107
- CU 04
- APTO-253
- GT19077
- ES-4000
- HSB-510
Introduction
Executive Summary
Proto oncogene protein c-myc inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Proto oncogene protein c-myc inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
RRx-001: EpicentRx Inc.
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
C41443: Teva Pharmaceutical Industries
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I and I/II)
Comparative Analysis
WP1066: Moleculin Biotech
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
ES-4000: Escend Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Proto oncogene protein c-myc inhibitors Key Companies
Proto oncogene protein c-myc inhibitors Key Products
Proto oncogene protein c-myc inhibitors- Unmet Needs
Proto oncogene protein c-myc inhibitors- Market Drivers and Barriers
Proto oncogene protein c-myc inhibitors- Future Perspectives and Conclusion
Proto oncogene protein c-myc inhibitors Analyst Views
Proto oncogene protein c-myc inhibitors Key Companies
Appendix
Executive Summary
Proto oncogene protein c-myc inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Proto oncogene protein c-myc inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
RRx-001: EpicentRx Inc.
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
C41443: Teva Pharmaceutical Industries
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I and I/II)
Comparative Analysis
WP1066: Moleculin Biotech
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
ES-4000: Escend Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Proto oncogene protein c-myc inhibitors Key Companies
Proto oncogene protein c-myc inhibitors Key Products
Proto oncogene protein c-myc inhibitors- Unmet Needs
Proto oncogene protein c-myc inhibitors- Market Drivers and Barriers
Proto oncogene protein c-myc inhibitors- Future Perspectives and Conclusion
Proto oncogene protein c-myc inhibitors Analyst Views
Proto oncogene protein c-myc inhibitors Key Companies
Appendix